Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2

Finn, Richard SRichard SFinnYau, ThomasThomasYauCHIH-HUNG HSUDe Toni, Enrico NEnrico NDe ToniGoyal, LipikaLipikaGoyalGalle, Peter RPeter RGalleQin, ShuKuiShuKuiQinRao, SujataSujataRaoSun, FangfangFangfangSunWang, ChunxiaoChunxiaoWangWidau, Ryan CRyan CWidauZhu, Andrew XAndrew XZhu2023-01-092023-01-092022-12-091083-7159https://scholars.lib.ntu.edu.tw/handle/123456789/627062Ramucirumab is indicated for patients with advanced hepatocellular carcinoma (HCC) and α-fetoprotein (AFP) ≥400 ng/mL following sorafenib. Here, we prospectively studied ramucirumab following non-sorafenib systemic therapies.enadvanced hepatocellular carcinoma (HCC); non-sorafenib; ramucirumab; α-fetoproteinRamucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2journal article10.1093/oncolo/oyac183361903312-s2.0-85143645548WOS:000863270500001https://api.elsevier.com/content/abstract/scopus_id/85143645548